Summary: Cigna Healthcare modified its External Counterpulsation coverage policy (policy 0058), effective May 16, 2026. Here's what billing teams need to do.
Cigna Healthcare updated policy 0058 governing Enhanced External Counterpulsation (EECP) — a non-invasive cardiac treatment used for refractory angina. This coverage policy change affects cardiology and cardiovascular billing teams who submit EECP claims to Cigna. The policy document does not list specific codes, so your team will need to pull the full policy text to confirm how your current charge capture aligns with the updated criteria before May 16, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | External Counterpulsation (0058) |
| Policy Code | 0058 |
| Change Type | Modified |
| Effective Date | 2026-05-16 |
| Impact Level | Medium |
| Specialties Affected | Cardiology, Cardiovascular Medicine, Cardiac Rehabilitation |
| Key Action | Pull the updated 0058 policy text and audit your EECP claims for alignment with revised medical necessity criteria before May 16, 2026 |
Cigna External Counterpulsation Coverage Criteria and Medical Necessity Requirements 2026
Enhanced External Counterpulsation, commonly called EECP, sits in a complicated spot in payer policy. Most major payers — including Cigna — have historically covered it under narrow criteria, and modifications to these policies almost always tighten the medical necessity bar or update which clinical scenarios qualify.
The Cigna external counterpulsation coverage policy under 0058 governs when EECP is considered medically necessary versus experimental or investigational. EECP involves pneumatic cuffs applied to the lower extremities that inflate and deflate in sync with the cardiac cycle. The goal is to increase diastolic pressure and reduce systolic load — effectively improving coronary perfusion in patients with refractory angina who have exhausted other options.
Cigna's historical position on EECP has centered on a narrow set of covered indications. Coverage has generally required that patients have chronic stable angina (Canadian Cardiovascular Society Class III or IV), that they've failed or are poor candidates for revascularization (CABG or PCI), and that they have documented coronary artery disease with objective evidence of myocardial ischemia. That's a high bar, and it exists because EECP has mixed evidence in broader populations.
The May 16, 2026 effective date of this modification means something changed in those criteria — whether it's a tightening of the required documentation, an update to the prior authorization process, or a shift in which indications Cigna considers experimental. Because the policy document does not include specific code-level data in the version available at publication, you need to access the full policy text directly at the source to understand exactly where the criteria shifted.
If your cardiology practice bills EECP for Cigna members, treat this modification as a red flag until you've read the updated text. A coverage policy modification on a historically narrow benefit like EECP rarely works in the provider's favor.
Prior authorization for EECP under Cigna has been required historically — and there's no reason to assume that requirement changed with this modification. If anything, prior auth scrutiny tends to increase when payers update policies for services with contested evidence bases. Confirm your prior authorization workflow reflects whatever the updated criteria require before you submit a single claim after May 16, 2026.
Cigna External Counterpulsation Exclusions and Non-Covered Indications
Cigna has historically classified EECP as experimental and investigational for several indications beyond chronic refractory angina. These have included:
| # | Excluded Procedure |
|---|---|
| 1 | Heart failure as a standalone indication (outside of angina) |
| 2 | Erectile dysfunction |
| 3 | Neurological conditions |
| 4 | Any indication not supported by the clinical evidence Cigna recognizes at the time of policy review |
The "experimental and investigational" designation carries real financial consequences. Claims submitted under excluded indications don't just get denied — they can trigger recoupment requests on previously paid claims if your documentation doesn't support the approved indication.
The real issue here is that EECP providers often have patients with overlapping diagnoses. A patient with refractory angina and heart failure needs clear documentation that the covered indication (angina) is the primary driver of the EECP treatment. Mixing indications in your clinical notes without clarity creates claim denial risk.
Until you've reviewed the updated 0058 policy text, assume the exclusion list is at least as broad as it was under the prior version — and possibly broader.
Coverage Indications at a Glance
Because the policy document available at publication does not include specific code data or a detailed indication-level breakdown, this table reflects Cigna's historically documented EECP coverage positions. Verify each row against the updated May 16, 2026 policy text before relying on this for billing decisions.
| Indication | Status | Notes |
|---|---|---|
| Chronic stable angina (CCS Class III–IV), failed or ineligible for revascularization, documented CAD with ischemia | Covered (historically) | Prior authorization required; documentation must be thorough |
| Heart failure as standalone indication | Not Covered / Experimental | Mixed evidence; Cigna has not historically covered this separately |
| Erectile dysfunction | Not Covered / Experimental | No recognized evidence base for EECP in this indication |
| Neurological conditions | Not Covered / Experimental | Outside the cardiovascular evidence base Cigna recognizes |
| EECP for indications not meeting clinical criteria | Not Covered | Claims denied; recoupment risk on prior paid claims |
Cigna External Counterpulsation Billing Guidelines and Action Items 2026
EECP billing is already high-scrutiny. A policy modification makes it higher. Here are the steps your billing team should take now.
| # | Action Item |
|---|---|
| 1 | Pull the full updated policy text immediately. Access the Cigna 0058 policy directly at the source document. The version available at publication does not include code-level data — but the full policy text almost certainly does. You need that text before the May 16, 2026 effective date. |
| 2 | Audit your current EECP claims against the updated criteria. Once you have the full policy text, compare your current charge capture and documentation workflows to the revised medical necessity criteria. Look for gaps — especially in documentation of failed revascularization attempts, CCS angina classification, and ischemia evidence. |
| 3 | Confirm your prior authorization process reflects the updated requirements. Prior authorization for EECP is standard under Cigna. Check whether the modification changed the required documentation for auth submission, the clinical criteria Cigna uses to approve or deny, or the authorization timeframes. Update your PA workflow before May 16, 2026. |
| 4 | Review your ICD-10 diagnosis code selection. External counterpulsation billing lives and dies on diagnosis coding. The ICD-10 codes on your claims must align precisely with the covered indication. If Cigna tightened the criteria with this modification, a diagnosis code that passed before May 16 may trigger a claim denial after. |
| 5 | Educate your ordering physicians on documentation requirements. The medical necessity documentation for EECP needs to come from the clinical notes — not just from a PA form. Physicians need to document CCS class, prior revascularization history or contraindications, and objective ischemia findings. If the updated policy added documentation requirements, get those in front of your cardiologists now. |
| 6 | Flag any pending EECP claims for Cigna members. If you have claims in process for dates of service near or after May 16, 2026, hold them until you've confirmed alignment with the updated policy. A denied claim under the new criteria is far more expensive to deal with than a delayed submission. |
| 7 | Talk to your compliance officer if you're uncertain. If your EECP volume under Cigna is significant, or if your patient population skews toward borderline indications, loop in your compliance officer before the effective date. This is not a policy change to interpret loosely. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for External Counterpulsation Under Policy 0058
The Cigna 0058 policy document available at publication does not list specific CPT, HCPCS, or ICD-10 codes. Do not use codes from other sources as a proxy — payer-specific policy documents define which codes fall under the policy, and using codes from CMS or another payer's policy is a claim denial risk.
Access the full 0058 policy text directly through Cigna's provider resources or the PayerPolicy source link to get the code-level detail. When you have the full text, build your code tables from that — not from third-party summaries.
For reference, external counterpulsation billing historically involves a HCPCS code for the EECP treatment sessions themselves. The number of sessions covered, the reimbursement per session, and the documentation requirements attached to each session are all governed by the policy criteria. Those details are in the full policy text.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.